NUREXONE BIOLOGIC INC.

Communiqués NurExone Biologic Inc. Deutsche Boerse AG

Actions

J90

CA67059R1091

Marché Fermé - Deutsche Boerse AG Autres places de cotation 16:18:47 05/07/2024			Varia. 5j.	Varia. 1 janv.
0,44 ^EUR	-0,45 %		0,00 %	+157,31 %

28/06	NurExone Biologic Inc. annonce une étude préclinique visant à explorer le potentiel des thérapies à base d'exosomes de NurExone dans la régénération des nerfs optiques endommagés	CI
29/05	NurExone Biologic Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Updates from NurExone: Growth Conference Presentation and Website Relaunch	05/07	AQ
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market	28/06	AQ
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development	21/06	AQ
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application	11/06	AQ
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders	04/06	AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	29/05	AQ
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	17/05	AQ
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	25/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	22/04	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	19/04	AQ
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	02/04	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	27/03	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	22/03	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	15/03	AQ
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	08/03	AQ
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	01/03	AQ
NurExone’s Intellectual Property Portfolio Expands	20/02	AQ
NurExone Launches Licensing Efforts for ExoTherapy Platform	14/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Sécurisez et Augmentez la Performance de vos Investissements grâce à notre Équipe d'Experts à vos Côtés

Sécuriser mes Investissements

fermer